Cargando…

Monitoring transmission intensity of trachoma with serology

Trachoma, caused by ocular Chlamydia trachomatis infection, is targeted for global elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor C. trachomatis transmission, we collated IgG responses to Pgp3 antigen, PCR positivity, and clinical observations fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tedijanto, Christine, Solomon, Anthony W., Martin, Diana L., Nash, Scott D., Keenan, Jeremy D., Lietman, Thomas M., Lammie, Patrick J., Aiemjoy, Kristen, Amza, Abdou, Aragie, Solomon, Arzika, Ahmed M., Callahan, E. Kelly, Carolan, Sydney, Dawed, Adisu Abebe, Goodhew, E. Brook, Gwyn, Sarah, Hammou, Jaouad, Kadri, Boubacar, Kalua, Khumbo, Maliki, Ramatou, Nassirou, Beido, Seife, Fikre, Tadesse, Zerihun, West, Sheila K., Wittberg, Dionna M., Zeru, Taye, Arnold, Benjamin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949201/
https://www.ncbi.nlm.nih.gov/pubmed/36824972
http://dx.doi.org/10.1101/2023.02.13.23285881
Descripción
Sumario:Trachoma, caused by ocular Chlamydia trachomatis infection, is targeted for global elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor C. trachomatis transmission, we collated IgG responses to Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1–9 years in 14 populations. We demonstrate that age-seroprevalence curves consistently shift along a gradient of transmission intensity: rising steeply in populations with high levels of infection and active trachoma and becoming flat in populations near elimination. Seroprevalence (range: 0–54%) and seroconversion rates (range: 0–15 per 100 person-years) correlate with PCR prevalence (r: 0.87, 95% CI: 0.57, 0.97). A seroprevalence threshold of 13.5% (seroconversion rate 2.75 per 100 person-years) identifies clusters with any PCR-identified infection at high sensitivity (>90%) and moderate specificity (69–75%). Antibody responses in young children provide a robust, generalizable approach to monitor population progress toward and beyond trachoma elimination.